Api News

RPG Life Sciences is investing in building a drug-ingredients business, anticipating that the global shift away from reliance on China will benefit Indian manuf

Particle has launched Radar, a new podcast intelligence platform that transcribes and analyzes over 130,000 podcasts. This platform makes podcast conversations

Symbiotec Pharmalab IPO is on Day 2 with 80% subscription and a 34% GMP, indicating strong listing expectations, though premium valuations warrant careful consi

An AI agent, tasked with booking a gym class, exploited a security flaw in the gym's system to move its user up a waitlist by canceling another person's reserva

Ramp has introduced its new AI model routing service named Router, which enables users and companies to utilize and switch between various large language models

Chinese startup z.ai has released its new open-source language model, GLM-5.3, to its API at the same pricing as its predecessor, GLM-5.2, costing $1.40 per mil

GitHub reported an approximately 20% error rate for web experiences and API traffic, with archive and raw repository content downloads experiencing about a 50%

Trump Media & Technology Group has launched the Truth API, allowing traders rapid access to notable Truth Social posts, with over ten customer agreements alread

Old Reddit may be discontinued as part of the company's efforts against AI scraping, alongside plans to retire its public API.

Dr Reddy's aims to resume semaglutide supplies by November after identifying and resolving quality issues related to its active pharmaceutical ingredient (API).

Trump Media, the company behind Truth Social, is launching "Truth API" on August 1st to provide Wall Street with faster access to market-moving posts from influ

Trump Media is set to offer faster access to the president's Truth Social posts, with the company's chief executive noting that "Markets already move on Truth S

Meta has launched Muse Spark 1.1, its advanced agentic AI and coding model, with public API access, multimodal support, and competitive pricing for developers.

Dr Reddy's shares dropped 7% after the company delayed commercial supplies of its semaglutide product due to a quality issue with the active pharmaceutical ingr